Cardinali Barbara, Tasso Roberta, Piccioli Patrizia, Ciferri Maria Chiara, Quarto Rodolfo, Del Mastro Lucia
Department of Medical Oncology, U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.
Department of Experimental Medicine (DIMES), University of Genova, 16132 Genova, Italy.
Cancers (Basel). 2022 May 7;14(9):2317. doi: 10.3390/cancers14092317.
Great improvement has been made in the diagnosis and therapy of breast cancer patients. However, the identification of biomarkers for early diagnosis, prognosis, therapy assessment and monitoring, including drug resistance and the early detection of micro-metastases, is still lacking. Recently, circulating microRNAs (miRNAs), circulating freely in the blood stream or entrapped in extracellular vesicles (EVs), have been shown to have a potential diagnostic, prognostic or predictive power. In this review, recent findings are summarized, both at a preclinical and clinical level, related to miRNA applicability in the context of breast cancer. Different aspects, including clinical and technical challenges, are discussed, describing the potentialities of miRNA use in breast cancer. Even though more methodological standardized studies conducted in larger and selected patient cohorts are needed to support the effective clinical utility of miRNA as biomarkers, they could represent novel and accessible tools to be transferred into clinical practice.
乳腺癌患者的诊断和治疗已取得了很大进展。然而,目前仍缺乏用于早期诊断、预后评估、治疗评估与监测(包括耐药性以及微转移的早期检测)的生物标志物。最近研究发现,在血液中自由循环或包裹于细胞外囊泡(EVs)中的循环微小RNA(miRNAs)具有潜在的诊断、预后或预测能力。在本综述中,我们总结了临床前和临床水平上与miRNA在乳腺癌中的适用性相关的最新研究结果。文中讨论了包括临床和技术挑战在内的不同方面,阐述了miRNA在乳腺癌中的应用潜力。尽管需要在更大规模且经过挑选的患者队列中开展更多方法标准化的研究,以支持miRNA作为生物标志物的有效临床应用,但它们可能成为可转化为临床实践的新型且易于获取的工具。